Pfizer beats Q4, FY '24 earnings estimates, stock flat in early trading
Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...
PFE Earnings: Pfizer Stock Jumps on Q4 Beats
Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...
Pfizer Q4 Results Beat Market; Confirms FY25 Outlook - Update
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Pfizer’s Covid Boost Overshadowed by Kennedy Threat to Vaccines
Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...
Pfizer beats profit estimates on cost cuts, COVID vaccine sales
On an adjusted basis, the company earned 63 cents per share for the three months ended Dec. 31, compared with the average ...
Pfizer outlines 2025 R&D milestones and oncology growth opportunities
Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...
Pfizer Shares Rise on Better-Than-Expected 4Q
Investors have been cool to Pfizer, with shares down some 50% since record highs in 2021. Pfizer Chief Executive Albert Bourla has been looking to turn around the company's performance, taking steps ...